UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Get essential year-end tax filing guidance for DRIP ETFs, including records to gather and strategies to reduce liabilities.
24,400 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Public narratives about famous moments often spark a larger lesson about money. This article uses the idea of terrenc...
When a growth stock down nearly 50% from its high looks tempting, it helps to separate hype from fundamentals. This g...
Alibaba shares slid about 7% after quarterly results, underscoring a push into AI and cloud infrastructure. Investors...
A major broker cuts Alibaba's target to $170 after a sharp drop in Q3 profits, driven by heavy AI investment. The clo...
Argus boosts Exxon Mobil's target to $169, signaling confidence in higher 2026 output from Permian and Guyana and a r...
Apple signals a strategic pivot, moving its flagship away from the iPhone toward ambient computing with Vision Pro an...
Investors are shifting focus from Intel to overlooked chip stocks delivering real cash flow and AI-driven demand, led...
NVIDIA and Alphabet reveal divergent AI strategies, highlighting hardware rails versus cloud-powered services, and si...
Wells Fargo lowers Meta's price target to 765 but preserves a bullish view as Meta reports strong Q1 FY2026 results a...
Investors are pricing rate hikes through 2027 as the Fed cuts outlook fades, reshaping bond yields and stock valuatio...
Dollar Tree beats expectations and lifts its full-year outlook, sending DLTR up sharply as the discount-store rally w...